CD19 and acute lymphoblastic leukemia: Two CAR-T-based therapies, i.e., axicabtagene ciloleucel and tisagenlecleucel, target CD19 and have been approved by the FDA in 2017 to treat non-Hodgkin’s lymphoma (NHLs) and relapsed acute lymphoblastic leukemia (ALL), respectively.